INTRODUCTION
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder. The disease process often causes the destruction of joints which can lead to considerable disability. Autoantibodies such as rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) are important diagnostic markers for RA and may also contribute to pathogenesis. 1 ACPA positive RA patients have more radiological damage and a lower chance to reach disease modifying anti-rheumatic drug (DMARD) free remission than ACPA negative RA patients. [2] [3] [4] [5] In pre-RA states such as arthralgia and undifferentiated arthritis, ACPA and RF are predictive factors for future progression towards RA. 6, 7 Recently, we discovered another autoantibody system present in RA patients, which
we designated anti-carbamylated protein antibodies (anti-CarP). 8 These antibodies target carbamylated proteins instead of citrullinated proteins. Carbamylation is a process in which lysines are converted into homocitrullines under the influence of cyanate. Homocitrulline is an amino acid which highly resembles citrulline. Cyanate can be formed in low concentrations from urea under physiological conditions or it can originate from the environment, for instance from car fumes. In inflammatory conditions it can be formed from thiocyanate catalyzed by myeloperoxidase released by for instance activated neutrophils. Whether or not anti-CarP antibodies are directly involved in the pathogenesis of RA is currently unknown.
In our previous paper, we reported that anti-CarP antibodies are present in both ACPA positive (74%) and negative (16%) RA patients. 8 In RA patients, they are a prognostic factor for a higher rate of joint destruction independent of ACPA.
However, at present it is unknown whether they exist in Arthralgia patients and could have predictive value in them. Therefore, we measured the presence of antiCarP antibodies and studied the association between anti-CarP antibody status and levels and the risk of eveloping RA in a cohort of anti-cyclic citrulline peptide 2 (aCCP2) antibodies and/or RF positive arthralgia patients.
MATERIALS AND METHODS

Study population
The inclusion procedure was as described before. 6 In short, 340 Caucasian patients from the Amsterdam area, without arthritis but with a positive aCCP2 antibody and/or IgM-RF status and (a history of) arthralgia were included. Absence of arthritis was confirmed by physical examination of 44 joints by a trained medical doctor and a senior rheumatologist. 9 Medical history, details of joint complaints and the number of tender joints were recorded. 10 Patients with arthritis as revealed by chart review or baseline physical examination, negative aCCP antibody and IgM-RF status on second analysis, previous treatment with DMARD or recent glucocorticoid treatment (< 3 months) were excluded. Patients were followed semi-annually in the first year and yearly thereafter for the development of RA according to the 2010 ACR/EULAR criteria. 1 In addition, extra visits were planned if (rheumatoid) arthritis developed. Healthy control sera were collected from Caucasian inhabitants of the Leiden area. The protocols were approved by the local ethics committee and informed consent was obtained.
Anti-CarP IgG antibody ELISA
Anti-CarP IgG antibodies in patients' and controls' sera were detected by ELISA as described before. 8 Briefly, Nunc Maxisorp plates (Thermo Scientific) were coated with 10 mg/mL fetal calf serum (FCS) (Bodinco) and carbamylated (Ca)-FCS at 4º
overnight. The plates were blocked with 1% bovine serum albumin (BSA) (Sigma) at 4º for 6 hours, followed by incubation with 1/50 diluted sera on ice overnight. Three hundred forty arthralgia patients were included and followed for a median 
DISCUSSION
Although arthralgia patients often have a benign disease course, a certain subset of these patients may progress to RA. Identifying this subset at an early stage is attractive, because intervention at this stage might prevent the development of RA.
As an established biomarker, the presence of ACPA increases the risk of converting to arthritis in arthralgia patients, but still only 27% of all ACPA positive arthralgia patients progress to arthritis after 1 year of follow-up. 6 We now studied whether anti-CarP antibodies are present in arthralgia patients and whether they are an additional risk factor for RA in these patients. We found that anti-CarP antibodies were present in arthralgia patients and that they were associated with a higher risk of developing RA independent of ACPA and IgM-RF status. Within the aCCP2
antibody negative subgroup, we did not observe a significant association between anti-CarP antibodies and RA, possibly due to the low number of RA cases in this group.
Limited by the nature of the cohort, we were unable to address the question whether anti-CarP antibodies can predict RA in aCCP2 antibody and RF double negative arthralgia patients. Another limitation is the 3 years median follow-up time, which is relatively short and may impact on the percentage of patients developing RA. However, we observed that with increasing follow-up time the percentage of arthralgia converting to RA decreases. Therefore we feel that this effect will be limited. A further concern could be that these patients might have subclinical arthritis at baseline, undetected by physical examination. However, we have previously seen that the frequency of ultrasound pathology was very low in this population and moreover, that ultrasound was not superior to physical examination in the prediction of RA.
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Our findings suggest that not only ACPA positivity, but also the presence of antiCarP antibodies can have clinical value in the prediction of RA in arthralgia patients.
Additionally, the presence of anti-CarP antibodies in persons at risk for RA provides a rationale for further studies on their potential pathogenic properties. Although the presence of anti-CarP antibodies associates with the risk to develop RA in ACPA-positive arthralgia patients, we previously did not obtain evidence that their presence associates with radiological progression in ACPA positive RA patients, which was only found in ACPA negative RA patients. 8 The reasons for these findings
are not yet known and require further replications, but they do resemble the observations with respect to ACPA fine specificity. [12] [13] [14] The ACPA recognition profile does not correlate with radiological progression in ACPA positive RA,
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number of citrullinated epitopes recognized by ACPA does associate with RA development in patients suffering from arthralgia or undifferentiated arthritis. 13, 14 Apparently, in the first stage of disease, the number of epitopes recognized and isotypes used by ACPA 5 as well as the number of auto-antibodies present are determining factors for disease progression, but matter less when a certain threshold has been passed, possibly explaining the lack of association in established RA. Despite the similarity between the presence of Anti-CarP antibodies and the broadening of ACPA fine-specificities with respect to prediction of RA, antiCarP antibodies are not a fine-specificity of ACPA as they are largely non-crossreactive towards defined (homo)citrullinated antigens. 15 Indeed the effect of antiCarP antibodies shown in arthralgia patients as described above is present after correcting the effect of anti-CCP2 antibodies as could be expected for two independent auto-antibody systems.
Together, our data reveal that anti-CarP antibodies are present before RA becomes clinically apparent as they can be found in patients suffering from arthralgia without signs of arthritis. Furthermore, their presence in this population is associated with the development of RA. 
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